Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zyprexa Goes Generic: Teva Fills "Basket" Of Doses With Dr. Reddy's Deal

Executive Summary

Teva Pharmaceutical Industries greeted the patent expiration of Lilly’s Zyprexa (olanzapine) by launching all six tablet doses of the antipsychotic, thanks to an agreement with Dr. Reddy’s Laboratories Ltd.

You may also be interested in...

Teva’s U.S. Generic Sales Rebound With Late-Year Launches, Ranbaxy Lipitor Deal

The Israel-based manufacturer saw its full-year U.S. generic revenues drop 32% due to expired marketing exclusivities and manufacturing problems at two plants. However, the fourth quarter brought a rebound, thanks to launches of generic Zyprexa and Combivir and a profit-sharing agreement on atorvastatin.

Ranbaxy Likely To Go Solo For Lipitor Launch; FDA Closer To Resolving Manufacturing Issues

Lilly Prepares For Zyprexa Expiration; Increases R&D Spend

Lilly's earnings are in line with analyst expectations, but higher costs cut into profits as the company prepares for a revenue decline.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts